Skip to content
lifestyle.bossesmag.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Ipsen Pharma
Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance
May 26, 2026
Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration
May 26, 2026
Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma
May 22, 2026
Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR
May 20, 2026
Ipsen appoints Michelle C. Werner as EVP, President of North America
May 19, 2026
←
Previous Page
1
2